TFRC and triple-negative breast carcinoma: These results support that 12b is a novel, promising, small molecule led compound targeting TfR1 against triple negative breast cancer cells worth further studying in the future, and the finding of the structure-activity relationship helps to design new more effective compounds against TfR1.